ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

ClinicalTrials.gov ID: NCT06644781

Public ClinicalTrials.gov record NCT06644781. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 11:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Study identification

NCT ID
NCT06644781
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Daiichi Sankyo
Industry
Enrollment
510 participants

Conditions and interventions

Interventions

  • Docetaxel Drug
  • Ifinatamab deruxtecan Drug
  • Irinotecan hydrochloride (HCl) Drug
  • Paclitaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 26, 2025
Primary completion
May 31, 2028
Completion
Oct 31, 2029
Last update posted
Jan 11, 2026

2025 – 2029

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
Providence Medical Foundation Fullerton California 92835 Recruiting
Henry Ford Health System Detroit Michigan 48202 Recruiting
Baptist Cancer Center Memphis Tennessee 38120 Recruiting
SCRI Oncology Partners Nashville Tennessee 37203 Recruiting
John Peter Smith Hospital Fort Worth Texas 76104 Recruiting
Virginia Cancer Specialists Fairfax Virginia 22031 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06644781, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 11, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06644781 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →